Compare · TMO vs VECO
TMO vs VECO
Side-by-side comparison of Thermo Fisher Scientific Inc (TMO) and Veeco Instruments Inc. (VECO): market cap, price performance, sector, and recent activity on the wire.
Summary
- TMO operates in Industrials, while VECO operates in Technology - the two are in different parts of the market.
- TMO is the larger of the two at $174.52B, about 46.8x VECO ($3.73B).
- Over the past year, TMO is up 14.9% and VECO is up 184.2% - VECO leads by 169.3 points.
- TMO has been more active in the news (17 items in the past 4 weeks vs 8 for VECO).
- TMO has more recent analyst coverage (25 ratings vs 11 for VECO).
- Company
- Thermo Fisher Scientific Inc
- Veeco Instruments Inc.
- Price
- $469.56-0.67%
- $60.97+4.30%
- Market cap
- $174.52B
- $3.73B
- 1M return
- -1.03%
- +5.59%
- 1Y return
- +14.92%
- +184.18%
- Industry
- Industrial Machinery/Components
- Industrial Machinery/Components
- Exchange
- NYSE
- NASDAQ
- IPO
- 1994
- News (4w)
- 17
- 8
- Recent ratings
- 25
- 11
Thermo Fisher Scientific Inc
Thermo Fisher Scientific Inc. offers life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and service worldwide. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets. Its Analytical Instruments segment provides instruments, consumables, software, and services for use in laboratory, on production line, and in field for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The company's Specialty Diagnostics segment offers liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, and calibration verification fluids; ImmunoCAP for allergy and asthma tests, and EliA for autoimmunity tests; dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; human leukocyte antigen typing and testing for organ transplant market; and healthcare products. Its Laboratory Products and Services segment provides laboratory refrigerators and freezers, ultralow-temperature freezers, and cryopreservation storage tanks; temperature control, sample preparation and preservation, centrifugation, and biological safety cabinet products; water analysis instruments; laboratory plastics products; laboratory chemicals; and pharma services. The company offers products and services through a direct sales force, customer-service professionals, electronic commerce, third-party distributors, and catalogs. It has a strategic alliance with the University of California, San Francisco. The company was incorporated in 1956 and is based in Waltham, Massachusetts.
Veeco Instruments Inc.
Veeco Instruments Inc., together with its subsidiaries, develops, manufactures, sells, and supports semiconductor and thin film process equipment primarily to make electronic devices worldwide. The company offers laser annealing, ion beam deposition and etch, metal organic chemical vapor deposition, single wafer wet processing and surface preparation, molecular beam epitaxy, and atomic layer deposition and other deposition systems, as well as packaging lithography equipment. Its process equipment systems are used in the production of a range of microelectronic components, including logic, dynamic random-access memory, photonics devices, power electronics, radio frequency filters and amplifiers, thin film magnetic heads, and other semiconductor devices. The company markets and sells its products to integrated device manufacturers and foundries; outsourced semiconductor assembly and test, hard disk drive, and photonics manufacturers; and research centers and universities. Veeco Instruments Inc. was founded in 1945 and is headquartered in Plainview, New York.
Latest TMO
- Thermo Fisher downgraded by HSBC Securities with a new price target
- Wolfe Research resumed coverage on Thermo Fisher with a new price target
- SEC Form SD filed by Thermo Fisher Scientific Inc
- Thermo Fisher Scientific Unveils Next-generation Innovations at ASMS 2026 to Accelerate the Path from Drug Discovery to New Therapies
- Thermo Fisher Scientific Inc filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- Director Weisler Dion J covered exercise/tax liability with 80 shares and was granted 499 shares, increasing direct ownership by 8% to 5,446 units (SEC Form 4)
- Director Sperling Scott M was granted 499 shares, increasing direct ownership by 0.72% to 69,479 units (SEC Form 4)
- Director Spar Debora L was granted 499 shares, increasing direct ownership by 24% to 2,610 units (SEC Form 4)
- Director Lynch Karen S was granted 499 shares, increasing direct ownership by 76% to 1,159 units (SEC Form 4)
- Director Keith R. Alexandra was granted 499 shares, increasing direct ownership by 24% to 2,602 units (SEC Form 4)
Latest VECO
- Director Hunter Gordon sold $430,643 worth of shares (6,752 units at $63.78), decreasing direct ownership by 19% to 28,210 units (SEC Form 4)
- CEO Miller William John sold $2,931,000 worth of shares (50,000 units at $58.62), decreasing direct ownership by 12% to 369,570 units (SEC Form 4)
- SEC Form SD filed by Veeco Instruments Inc.
- Director Hunter Gordon sold $1,091,360 worth of shares (17,714 units at $61.61), decreasing direct ownership by 34% to 34,962 units (SEC Form 4)
- SVP, GLOBAL SALES & SERVICE Wilkerson Susan sold $2,203,752 worth of shares (35,723 units at $61.69), decreasing direct ownership by 45% to 42,974 units (SEC Form 4)
- SVP - PRODUCT LINE DEVELOPMENT Devasahayam Adrian sold $334,369 worth of shares (5,407 units at $61.84), decreasing direct ownership by 5% to 95,115 units (SEC Form 4)
- Veeco Announces Upcoming Investor Events
- Director Damore Richard A sold $2,653,088 worth of shares (43,701 units at $60.71), decreasing direct ownership by 28% to 112,594 units (SEC Form 4)
- Director Hunter Gordon sold $1,754,496 worth of shares (29,532 units at $59.41), decreasing direct ownership by 36% to 52,676 units (SEC Form 4)
- Director St Dennis Thomas sold $86,702 worth of shares (1,400 units at $61.93), decreasing direct ownership by 2% to 61,697 units (SEC Form 4)